This retrospective study (n=101) of inpatients with treatment-resistant depression (TRD) found that intranasal esketamine led to significant reductions in depression severity, with 28.8% achieving response and 19.3% remission. Older age was associated with greater remission likelihood, and extended induction beyond eight sessions appeared particularly beneficial for older patients and those with psychiatric comorbidities, with no serious adverse events observed.
- Published
- Journal
- BMC Psychiatry
- Authors
- Baune, B. T., Rosemann, K., Hefter, D., Tonkul, M., Kavakbasi, E.